François Liebaert
Geen lopende functies
Profiel
François Liebaert served as the Chief Operating Officer & VP-Business Development at BioSystems International SAS.
Prior to that, he was the VP-Medical Affairs, Research & Devel at IntegraGen SA. He holds an MBA from École des Hautes Études Commerciales de Paris and a doctorate from Université de Lille II, which he received in 1985.
Eerdere bekende functies van François Liebaert
| Bedrijven | Functie | Einde |
|---|---|---|
BioSystems International SAS
 BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Operationeel Directeur | - |
| INTEGRAGEN | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van François Liebaert
| Université de Lille II | Doctorate Degree |
| École des Hautes Études Commerciales de Paris | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INTEGRAGEN | Health Services |
| Bedrijven in privébezit | 1 |
|---|---|
BioSystems International SAS
BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Health Technology |
